Loading
5-alpha-reductase turns testosterone into the more potent dihydrotestosterone inside the prostate; finasteride and dutasteride block it, and two large trials showed they cut prostate cancer diagnoses by about a quarter while raising concern about high-grade tumours.
Steroid 5-alpha-reductase type 2 converts testosterone to dihydrotestosterone, the androgen that drives prostate growth. Finasteride (type 2 selective) and dutasteride (types 1 and 2) are approved for benign prostatic enlargement and were tested for prevention in the Prostate Cancer Prevention Trial and the REDUCE trial, where they reduced the overall incidence of prostate cancer but were associated with a small excess of high-grade cancers, so neither is approved for prevention. In castration-resistant prostate cancer, tumour cells raise their own 5-alpha-reductase and other steroidogenic enzymes to make androgens, part of the rationale for abiraterone and the newer androgen receptor blockers.
In plain words · 5-alpha-reductase turns testosterone into the more potent dihydrotestosterone inside the prostate; finasteride and dutasteride block it, and two large trials showed they cut prostate cancer diagnoses by about a quarter while raising concern about high-grade tumours.
5-alpha-reductase turns testosterone into the more potent dihydrotestosterone inside the prostate; finasteride and dutasteride block it, and two large trials showed they cut prostate cancer diagnoses by about a quarter while raising concern about high-grade tumours.
A membrane enzyme of the endoplasmic reticulum in prostate, genital skin and hair follicles; it is NADPH-dependent and genetic loss causes a disorder of sex development.
No product in this corpus aims at 5-alpha-reductase type 2 (SRD5A2) yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Tumour-associated overexpression: HPA finds the RNA group enriched in cancer (Liver Hepatocellular Carcinoma (TCGA), Prostate Adenocarcinoma (TCGA)) and group enriched in normal epididymis, fallopian tube, liver, prostate, so the tumour and the normal tissue it comes from share the target and the medicine relies on the difference in level. HPA SRD5A2: RNA group enriched (epididymis 22 nTPM, fallopian tube 19 nTPM, liver 57 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Prostate cancer); Open Targets associates it with 3 specific cancer types at or above 0.5 (benign prostatic hyperplasia, prostate carcinoma, prostate cancer); the corpus evidence decides and the Open Targets list is quoted for comparison. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas SRD5A2 tissue; Human Protein Atlas SRD5A2 pathology; Open Targets ENSG00000277893 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Andersson et al, Nature, 1991, "Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism". Source.
A membrane enzyme of the endoplasmic reticulum in prostate, genital skin and hair follicles; it is NADPH-dependent and genetic loss causes a disorder of sex development.
RNA: group enriched (epididymis 22 nTPM, fallopian tube 19 nTPM, liver 57 nTPM, prostate 16 nTPM, seminal vesicle 17 nTPM), detected in some normal tissues.
No normal tissue stained high.
RNA group enriched: Liver Hepatocellular Carcinoma 5 pTPM, Prostate Adenocarcinoma 5 pTPM.
No cancer sample stained medium or high.
HPA SRD5A2 tissue · HPA SRD5A2 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Prostate cancer | host% | Host enzyme in normal and malignant prostate; finasteride and dutasteride were tested for prevention, not as a tumour marker | cancer.gov |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
Query for this target: (TITLE:"5-alpha-reductase type 2" OR ABSTRACT:"5-alpha-reductase type 2" OR TITLE:"SRD5A2" OR ABSTRACT:"SRD5A2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about 5-alpha-reductase type 2 (SRD5A2), not a curated reading list.
Shares Androgen receptor, Prostate cancer.
Shares Abiraterone acetate, Prostate cancer.
Shares CYP17A1 (17-alpha-hydroxylase/17,20-lyase), Androgen receptor, Prostate cancer.
Shares Abiraterone acetate, Prostate cancer.
Shares Abiraterone acetate, Prostate cancer.
Shares CYP17A1 (17-alpha-hydroxylase/17,20-lyase), Prostate cancer.
Shares Abiraterone acetate, Androgen receptor, Prostate cancer.
Shares CYP17A1 (17-alpha-hydroxylase/17,20-lyase), Androgen receptor, Prostate cancer.